Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|April 27, 2012
The Nexera MP UHPLC for LC/MS analysis in drug detection processes
Shimadzu has introduced the Nexera MP UHPLC as a Front End system for LC/MS. The Nexera MP is perfect for LC/MS analysis conducted in pharmacokinetics and synthesis stages in drug detection processes.
Advertisement
The Nexera MP UHPLC for LC/MS analysis in drug detection processes
Shimadzu has introduced the Nexera
The new SIL-30ACMP Multiplate Autosampler used in the Nexera MP is best suited for
Additional outstanding features
Efficient sample preparation
through excellent injection repeatability with micro volume injections streamlining the preparation process.
Two or more analyzers share one system
supporting the reduction of energy consumption and operation costs.
Column oven setting to the MS position
enabling achievement of ultra-high-speed, high-separation LC/MS analysis while maximizing the system’s separation performance.
The
For more details please visit
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement